Stock LXEO LEXEO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Lexeo Therapeutics, Inc.

Equities

LXEO

US52886X1072

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-23 EDT 		5-day change 1st Jan Change
15.48 USD +2.11% Intraday chart for Lexeo Therapeutics, Inc. +10.89% +15.35%
05-09 Lexeo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-01 Certain Options of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024. CI

Evolution of the average Target Price on Lexeo Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

3cf3d63.Bswha-rv9-YBihNxcc1GfYB_R9Q7ucrRqzg6vHr4SuM.RPRODKzcpq5LvicpPvoMDPMHNeVy9Oed6gxo5E7VBoFy-kUp3b-Yr0nlQg~8fa324d887e846696afea640fbde2a56

Analyst Recommendations on Lexeo Therapeutics, Inc.

RBC Raises Price Target on Lexeo Therapeutics to $24 From $22, Cites 'Solid' Friedreich's Ataxia Data; Outperform, Speculative Risk Kept MT
Chardan Initiates Lexeo Therapeutics With Buy Rating, $23 Price Target MT
Stifel Starts Lexeo Therapeutics With Buy Rating, $20 Price Target MT
RBC Initiates Lexeo Therapeutics at Outperform, Speculative Risk With $22 Price Target Amid 'Undemanding' Valuation, Upcoming Catalysts MT
JPMorgan Starts Lexeo Therapeutics With Overweight Rating, $20 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
15.48 USD
Average target price
21.4 USD
Spread / Average Target
+38.24%
High Price Target
24 USD
Spread / Highest target
+55.04%
Low Price Target
19 USD
Spread / Lowest Target
+22.74%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Lexeo Therapeutics, Inc.

RBC Capital Markets
Chardan Research
JPMorgan Chase
Stifel Nicolaus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. LXEO Stock
  4. Consensus Lexeo Therapeutics, Inc.